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The use of scale-down models is essential for the development, characterization and continuous improvement
of commercial cell culture processes. A model demonstrated to be predictive of large-scale performance is
advantageous as small-scale data can be used to support process investigations and changes, reduce costs
and consequently accelerate new therapies to market. Aligning geometric aspect ratios and dimensionless
engineering parameters improved the overall scale-down model representation for key process outputs such as
pCO2 accumulation and cell viability. Despite these changes, the revised scale-down model did not fully match
the large-scale process lactate accumulation. Interestingly, it was demonstrated that pCO2 accumulation at
small-scale reduced net lactate consumption, however pCO2 accumulation alone was not sufficient to fully
match the absence of metabolic shift observed at large-scale. Small-scale pH ranging studies demonstrated that
at settings above the large-scale process set point, the scale-down reactors had lactate profiles more closely
matching the commercial process. Conversely, a lower pH set point in the commercial-scale reactor combined
with an improved sparging strategy to remove CO2 had a transient increase in net lactate consumption, falling
short of a metabolic shift. Combined, these data suggest that physicochemical differences between small and
large scale bioreactors are contributing to the differences in metabolic behavior seen in this process. A
metabolomic approach was used to elucidate the root cause of metabolic difference between scales. A range of
pH settings from 6.8-7.3 were evaluated in the 5L scale down model of the commercial process. Samples from
the commercial process operated at different pH set points were also obtained and included in the study.
Results of metabolic profiling and hypothesis explaining the metabolic differences observed between scales will
be presented.

